A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX).

Trial Profile

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Cangrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Myocardial infarction; Stent thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CHAMPION; CHAMPION-PHOENIX; PHOENIX
  • Sponsors The Medicines Company
  • Most Recent Events

    • 12 Mar 2018 Results assessing safety and efficacy of Cangrelor for patients undergoing single vessel versus multi vessel percutaneous coronary intervention presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 02 Nov 2017 Results assessing the Impact of Coronary Calcification Severity on Clinical Outcomes After Contemporary PCI, presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 18 Jul 2017 Results of a prespecified subgroup analysis assessing efficacy and safety of cangrelor in the subgroup of patients who received unfractionated heparin (UFH) during PCI (n=7569) published in the American Journal of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top